Company* (Country, Symbol)

Company* (Country, Symbol)

Type/Product Area

Terms/Details (Date)

3-Dimensional Pharmaceuticals Inc. (DDDP)

Cyprotex Ltd. (UK)*

Collaboration for the use of Cyprotex's computerized methods for the prediction of human pharmacokinetics

The collaboration will focus on the application of Cyprotex's ADME prediction methods along with 3DP's Discover Works small-molecule drug discovery process to improve preclinical drug optimization (9/6)

4SC AG (Germany)*

Axxima Pharmaceuti-AG (Germany)*

Research collaboration to identify small-molecule kinase inhibitors for the treatment of human cyto-megalovirus infections

Axxima will develop and commercialize any resulting anti-infective HCMV kinase inhibitors; 4SC will receive milestone and royalty payments (9/10)

Affymetrix Inc. (AFFX)

Millennium Pharmaceuticals Inc. (MLNM)

Four-year research and development access agreement to develop a new generation of Affymetrix's GeneChip

Affymetrix is giving Millennium preferred and pric-ing to the gene expression platform, in return for a volume commitment to Gene-Chip (10/23)

Agenix Ltd. (Australia)*

Immunomedics Inc. (IMMU)

Nonexclusive license agreement giving Agenix access to Immunomedics' technology

The technology covers the labeling of antibodies with the radioisotope technetium (10/18)

Agilent Technologies Inc. (NYSE:A)

Incyte Genomics Inc. (INCY)

Expanded licensing agreement to further Agilent's development and commercialization of gene expression microarrays using Incyte's gene patent portfolio and genomic databases

Incyte will receive additional license fees, as well as royalties on sales of Agilent micro arrays (9/17)

Alexion Pharmaceuticals Inc. (ALXN)

Novagen Inc.*

Agreement for exclusive worldwide commercial rights to technology that allows the rapid discovery of antibody drug candidates

Alexion's license covers human therapeutic antibodies (10/11)

Alkermes Inc. (ALKS)

Bioject Medical Technologies Inc. (BJCT)

Development agreement to advance Alkermes' compounds

The companies will develop up to three drugs using Bioject's Iject, along with other needle-free systems; Alkermes will provide monthly payments to Bioject, adding cash as milestones are met; a commercial supply agreement for Iject is included in the deal (10/16)

AlleCure Corp.*

BD Biosciences (division of Becton, Dickinson & Co.; NYSE:BDX)

Research collaboration to develop assays in support of AlleCure's AlleVax treatments for allergies and various autoimmune diseases

The work will focus on the development of laboratory tests that may be used for allergy diagnosis, confirmation of vaccine efficacy and continued patient monitoring before, during and after immunotherapy (9/11)

Amarillo Biosciences Inc. (OTC BB: AMAR)

Atrix Laboratories Inc. (ATRX)

Licensing agreement providing the rights to oral low-dose interferon-alpha for the treatment of Behcet's disease and oral papillomavirus warts in HIV-positive patients

Atrix paid $485,000 for licensing orphan drug designations and clinical studies; Atrix will fund the research, and Amarillo will receive payments for specific clinical and regulatory milestones and will receive royalties (10/2)

Amersham Pharmacia Biotech (unit of Nycomed Amersham plc; NYSE:NYE)

Aurora Biosciences Corp. (subsidiary of Vertex Pharmaceuticals Inc.; VRTX)

Agreement to commercialize their combined Green Fluorescent Protein technology, which is used to accelerate drug discovery and development

The agreement will allow both companies to broaden access to GFP technology (9/10)

Antisoma plc (UK)*

Cancer Research Ventures Ltd. (UK)*

Licensing agreement for DMXAA, a vascular targeting agent

Antisoma in-licensed the product, which has completed two Phase I studies and was seen to control the growth of tumors in animal models (8/30)

Aquasearch Inc. (OTC BB: AQSE)

Ancile Pharmaceuticals Inc.*

Intent for an agreement to develop microalgae-based botanical drugs

The alliance will combine Aquasearch's pipeline of microalgae products and Ancile's drug development knowledge and technology platform that consists of methods for characterizing and standardizing botanical drug substances (9/25)

Array BioPharma Inc. (ARRY)

Vertex Pharmaceuticals Inc. (VRTX)

Agreement to discover and develop small-molecule drugs for two targets in the phosphatase protein family area

Array will be responsible for initial drug discovery, while Vertex can conduct its own research in the area and will be responsible for clinical development and commercialization; Array will receive an up-front fee and research funding for three years, as well as milestone payments (9/5)

Artificial Life Inc. (OTC BB: ALIF)

BeFutur Biotechnologies SA (Switzerland)*

Partnership agreement for stem cell research

The companies will cooperate on stem cell research, simulation and analysis of cell growth patterns, regenerative medicine and product and vaccine development (10/15)

Atugen AG (Germany)*

Arena Pharmaceuticals Inc. (ARNA)

Agreement to evaluate the use of Atugen's technology for Arena's research and development in the area of G protein-coupled receptors

Atugen plans to knock down the expression of central nervous system gene targets provided by Arena, which plans to use the GeneBloc antisense molecules to evaluate gene function in CNS in vivo models (9/19**)

Berna Biotech Ltd. (Switzerland)*

Bachem Ltd. (Switzerland)*

Joint venture agreement for developing therapeutic and prophylactic peptide vaccines

Companies are investing CHF20M (US$12.13M) to fund the joint venture, which will focus on projects in melanoma, malaria, hepatitis C and Alzheimer's disease (10/24**)

Biacore International AB (Sweden; BCOR)

Axiom Bio-technologies Inc.*

Agreement giving Biacore an exclusive license to all of Axiom's fluorescent cell-based assay technology with the exception of flow cytometry-based applications

Biacore's goal is to drive the commercialization of the technology, which is complementary to Biacore's own molecular-based assay systems (9/28)

BioMarin Pharmaceutical Inc. (BMRN)

IBEX Technologies Inc. (Canada; TSE:IBT)

Agreement for IBEX's pharmaceutical assets

BioMarin is paying $10.5M ($8.5M in BioMarin stock) for IBEX's assets, including Neutralase, and has promised another $9.5M based on product approvals (10/10)

Biovation Ltd. (UK)*

Micromet AG (Germany)*

Research agreement for Biovation to apply its DeImmunisation technology to therapeutic proteins designed by Micromet

Biovation will earn research revenues, and will receive license fees and potential milestone payments (8/28)


Genentech Inc. (NYSE:DNA)

Exclusive rights agreement to develop an atrial natriuretic factor peptide technology

The technology has been shown to have therapeutic potential in treating acute congestive heart failure, acute renal failure and renal hypertension (9/4)

Celera Genomics Group (NYSE:CRA)

Sagres Discovery*

Multiyear subscription agreement to allow Sagres scientists to access the Celera Discovery System

Financial terms were not disclosed (10/1)

Celera Genomics Group (NYSE:CRA)

Structural GenomiX Inc.*

Multiyear marketing and distribution partnership for ModBase, SGX's database containing more than 310,000 computationally modeled protein structures

Celera will offer ModBase as part of its Celera Discovery System (10/1)

Cellectis SA


genOway SA


Worldwide nonexclusive licensing

agreement for the patent EP419621

The patent covers the use of homologous

recombination for the development of

cellular and animal models (10/24)

Cellectis SA


Zentaris AG


Worldwide license agreement that

gives Zentaris rights to patents covering single long terminal repeats, a technology for gene transfer

Zentaris will use the technology to improve

its existing gene therapies for cancer (8/30)

Cel-Sci Corp. (AMEX:CVM)

Biomedex Inc.*

Joint development agreement to develop and manufacture rapid anthrax human screening and rapid anthrax human diagnostic tests

Biomedex will be responsible for securing both the necessary funding for the project and access to the reagents and materials required for the development projects (10/24)

Chiron Corp. (CHIR)

Medivir AB (Sweden)*

Collaboration centered on hepatitis C virus infections in which compound libraries from Medivir will be screened in Chiron's HCV assays

Chiron may choose to extend support beyond the initial one-year agreement; it also has an option to secure exclusive worldwide commercialization rights and could pay license and milestone fees totaling more than $10M, as well as royalties (8/30)

ConjuChem Inc. (Canada; TSE:CJC)

Heska Corp. (HSKA)

Research collaboration to develop a DAC compound for an undisclosed veterinary application

Heska will conduct compound testing and optimization studies for a 12-month period; Heska will have the option to negotiate a license and development agreement; ConjuChem received an undisclosed up-front payment (10/10)

Corvas International Inc. (CVAS)

Dyax Corp. (DYAX)

Collaboration to develop novel cancer therapeutics focused on serine protease inhibitors

The companies will assume joint development of any product candidates that may be identified and will share commercialization rights and profits from any marketed products; Dyax will use its phage display technology to identify small proteins, peptides and antibodies that bind to two serine protease targets isolated and characterized by Corvas; Corvas will apply its expertise in target validation and preclinical biology (9/20)

Deltagen Inc. (DGEN)

Hyseq Inc. (HYSQ)

Agreement in which Deltagen will research and develop about 200 novel secreted proteins provided by Hyseq

Hyseq will pay Deltagen about $10M in research and development payments over two years; Deltagen will receive about $10M in equity proceeds from the sale of 1.51M shares of common stock to George Rathmann, chairman of Hyseq; companies will share some costs and split equally any targets developed (10/10)

Dendreon Corp. (DNDN)

Geron Corp. (GERN)

Licensing agreement for the use of human telomerase as an antigen in Dendreon's therapeutic cancer vaccines

Dendreon has three cancer vaccines in clinical trials, including Provenge to treat prostate cancer (10/23)

Devgen NV (Belgium)*

Metabolex Inc.*

Research collaboration in which each company will employ its respective technology platforms to evaluate the other's compounds, in hopes of more rapidly assessing potential therapeutic utility of the compounds in diabetes

Devgen will analyze Metabolex compounds and Metabolex will analyze Devgen compounds; each party will retain ownership rights to its compounds (9/10)

Discovery Partners International Inc. (DPII)

The Genetics Co. Inc. (Switzerland)*

Collaborative research agreement to identify drug leads for the treatment of colon cancer

The goal is to test thousands of chemical substances in a high-throughput screen for their ability to block the activity of a critical protein and to inhibit uncontrolled cell division (9/24)

DoubleTwist Inc.*

GPC Biotech AG (Germany)*

Licensing agreement for Double-Twist's Prophecy database and tools suite

Prophecy provides GPC access to annotated public genome data (10/16)

Drug Royalty Corp. Inc. (Canada; TSE:DRI)

Celgene Corp. (CELG)

Agreement giving Drug Royalty a new royalty interest in worldwide sales of Celgene's Thalomid

Drug Royalty acquired the interest for $4.7M; the term of the agreement is tied to issued U.S. patents, the latest of which will expire in 2015 (10/9)

Endovasc Ltd. (OTC BB: ENDV)

CytoGenix Inc.*

Cooperative research and development agreement in which Endovasc will use its liposome technology to encapsulate the CytoGenix single-strand DNA expression systems, producing unmodified strands of ssDNA for therapeutic applications

The goal is to protect the ssDNA from destruction by exo- and endo-nucleases found on the skin and in the bloodstream (9/10)

Entelos Inc.*

Zen-Bio Inc.*

Research collaboration to study human fat cells in an effort toward developing new obesity therapeutics

The agreement may entail co-marketing, co-publication and the co-delivery of validated drug targets or candidates to pharmaceutical companies; the companies would evenly split research funding, milestones and royalties (10/8)

Epicyte Pharmaceutical Inc.* and Dow Chemical Co.

Centocor Inc.*

Agreement to evaluate production of a therapeutic human monoclonal antibody in plants

The agreement involves Epicyte's Plantibody technology; Centocor has the option to enter into an exclusive commercial supply agreement for a variety of clinical indications (9/4)

Epimmune Inc. (EPMN)

Anosys Inc. (formerly AP Cells)*

Nonexclusive license agreement to certain cancer antigens for use in Anosys' cancer therapy program

The license covers certain patented and non-patented rights to Epimmune's universal breast, colon, lung and prostate epitope packages for use in ex vivo cancer therapy; the license is worldwide, except for Japan, and the agreement includes an up-front license fee, milestones and royalties (9/19)

Exelixis Inc. (EXEL)

Scios Inc. (SCIO)

Four-year collaboration with Scios to develop a variety of lead compound structures for both companies

Exelixis will receive a fee per compound in addition to an up-front payment; the deal also gives each company the right to use the compounds in collaborations with other companies (10/8)

GeneData AG (Switzerland)*

DiaDexus Inc.*

License agreement for the GeneData Expressionist microarray data analysis system

The system is designed to rapidly screen through functional genomics data in order to determine genes that are the basis for disease (9/4)

GeneFormatics Inc.*

Bruker BioSpin Corp., Bruker AXS Inc. and Bruker Daltonics Inc. (BDAL)

Partnership to develop next-generation technologies for the analysis of 3-dimensional protein structures and the supply of various research infrastructure systems

The Bruker companies will make equity investments in GeneFormatics' Series C round of financings, and GeneFormatics will make equity cross investments in Bruker AXS and Bruker Daltonics (10/3)

Genencor International Inc. (GCOR)

Integrated Genomics Inc.*

Licensing agreement for three microbial genome sequencing technologies

Genencor will have access to Integrated Genomics' Aspergillus niger genome sequence data, the ERGO bioinformatics suite and Genome Explorer (9/26)

Genmab A/S (Denmark; CSE:GEN)

Immunex Corp. (IMNX)

Collaboration to discover and develop an antibody against an Immunex cancer target to treat lymphoma

Genmab will be responsible for developing the antibody, HuMax-Lymphoma, through Phase II trials; Immunex will have an exclusive option to be responsible for completing the clinical development, and it would pay Genmab a license fee, milestones and share profits if it is commercialized (10/8)

Genmab A/S (Denmark; CSE:GEN)

Scancell Ltd. (UK)*

Collaboration to develop fully human antibodies to cancer targets identified by Scancell

The first antibody product will target Lewis (y/b), a target overexpressed on breast, lung, colon and ovarian cancers; the companies will share development costs and commercialization rights (10/9)

Genome Therapeutics Corp. (GENE)

Biosearch Italia S.p.A. (Italy)*

Agreement for the U.S. and Canadian rights to ramoplanin, which is in Phase III for prevention of bloodstream infections

Genome Therapeutics will pay an initial $2M plus milestone payments up to $8M in cash and notes convertible into its stock; Genome Therapeutics also is under obligation to purchase bulk material from Biosearch, to fund the clinical trials and to pay a royalty on product sales (10/9)

Genomics Collaborative Inc.*

Cypress Bioscience Inc. (CYPB)

Agreement to provide DNA banking services

Genomics will provide Cypress with clinical research support enabling the collection, processing and storage of DNA, cerebral spinal fluid and lymphocyte transformation (10/24)

Genomics Collaborative Inc.*

Specialty Laboratories Inc. (NYSE:SP)

Research collaboration to study the clinical significance of new laboratory markers of disease

The study will combine GCI's high-throughput genetic analysis tools and specimen resources with Specialty's test development and commercialization expertise (9/5)

Gilead Sciences Inc. (GILD)

Archemix Corp.*

Out-licensing agreement for Gilead's intellectual property rights under the SELEX (Systemic Evolution of Ligands Through Exponential Enrichment) process patent estate

Gilead will receive $17.5M in cash, as well as warrants in Archemix; the agreement provides exclusive rights to the SELEX process, including therapeutic and other commercial applications (10/24)

Hyalose LLC (unit of Emergent Technologies Inc.)*

Novozymes A/S (Denmark)*

Multimillion-dollar joint development and option agreement to genetically produce hyaluronic acid and its variations based on Hyalose recombinant technology

Hyalose will receive from $8M to $10M if all options and milestones are met; it also will receive royalties from the product's commercialization (8/29)

Hybrigen Inc.*

Bionomics Ltd. (Australia)*

Letter of intent to negotiate the terms of a collaboration to discover drug targets in breast cancer

Program will be based on genes identified and patented by Bionomics, focused initially on the TSG18 and BNO1 genes (9/20)

Imaging Research Inc. (Canada)*

Genicon Sciences Corp.*

Software licensing, promotion and distribution agreement for Imaging Research's ArrayVision microarray analysis software and Genicon's resonance light scattering signal detection technology

Imaging Research will supply ArrayVision to Genicon for promotion and commercialization in concert with resonance light scattering technology (10/16)

ImmuneTech Inc.*

Luminex Corp. (LMNX)

Partnership permitting Immune Tech to develop and commercialize a line of allergy tests based on Luminex's Multi-Analyte Profiling technology

ImmuneTech gains access to LabMAP to perform allergy testing services and to produce allergy testing panels (9/26)

Incyte Genomics Inc. (INCY)

Epoch Biosciences Inc. (EBIO)

Alliance designed to leverage the intellectual property assets of both companies

Agreement gives Epoch access to LifeSeq Gold and ZooSeq to allow development of oligonucleotide probes based on Incyte's gene content; Epoch will be a preferred provider of the probes; it also includes a supply of Epoch Eclipse Probe Systems for Incyte internal development purposes (10/10)

Incyte Genomics Inc. (INCY)

Galapagos Genomics NV (Belgium)*

Extended functional genomics collaboration based on the LifeSeq collection

Galapagos will construct a custom adenoviral library harboring genes relevant to Incyte's in-house drug target discovery and validation efforts (9/10)

Incyte Genomics Inc. (INCY)

Genentech Inc. (NYSE:DNA)

Licensing agreement for patent rights covering therapeutic antibodies to four proteins discovered by Incyte

Incyte is entitled to receive milestones for clinical development and will be eligible for undisclosed royalties on any commercialized products (10/23)

InterMune Inc. (ITMN)

Maxygen Inc. (MAXY)

Collaboration for the development of the next generation of Actimmune

InterMune will take into the clinic the potential products created by Maxygen during the next two or three years; InterMune will pay for development and keeps worldwide commercialization rights giving Maxygen upfront license fees, research funding and milestone payments that could exceed $60M, as well as royalties (9/5)

Invitrogen Corp. (IVGN)

Gryphon Sciences*

Nonexclusive sublicense for Native Chemical Ligation patents for the synthesis of proteins using chemical means

Invitrogen plans to use the patents to develop products to facilitate molecular biology research in proteomics (10/19)

Isogenica Ltd. (UK)*

Affitech A/S (Norway)*

Collaboration and licensing agreement for the development and commercialization of Isogenica's Covalent Display Technology

Affitech will use CDT to generate high-affinity human antibodies; Isogenica will get license fees and royalties, as well as scientific input for its research and development program (10/1)

Jomed NV (Switzerland; SWX:JOM)

OxiGene Inc. (OXGN)

Collaboration to research restenosis inhibitors, integrating Jomed's stent technology with OxiGene's platform of vascular targeting agents

Jomed will perform proof-of-concept studies using OxiGene's vascular targeting agents on drug-eluting stents (9/4)

LION bioscience AG (Germany; LEON)

Genomics Collaborative Inc.*

Licensing agreement for LION's SRS platform

The platform will be used to access GCI's databases of patient clinical and sample information, as well as public biological data sources via one portal (8/30)

Medarex Inc. (MEDX)

Incyte Genomics Inc. (INCY)

Collaboration to develop antibodies using Medarex's UltiMAb Human Antibody Development System

Each company equally will assume responsibility for costs associated with development, and the companies will share commercialization expenses and profits (10/18)

MediChem Life Sciences Inc. (MCLS)

Cephalon Inc.*

Service agreement for protein crystallography of an undisclosed target

MediChem will receive technology access fees, full-time employment funding and milestone payments (10/24)

MediChem LifeSciences Inc. (MCLS)

Rigel Pharmaceuticals Inc. (RIGL)

Two-year collaboration in structural proteomics for drug development, initially focused on ubiquitin ligases

MediChem will express, purify and co-crystallize Rigel protein complexes, and then determine their structures, as well as co-crystallize several Rigel small-molecule drug leads with protein complexes; Rigel will pay MediChem for research, as well as milestones (9/5)

Metabasis Therapeutics Inc.*

ICN Pharmaceuticals Inc. (NYSE:ICN)

Licensing agreement for Metabasis' hepatitis B compound

Metabasis was paid initial fees and could be paid milestones in the $20M to $30M range, as well as royalties; ICN will pay all development costs (10/2)

Microscience Ltd.*

Anadis Ltd. (Australia)*

Licensing agreement for high-speed identification technology for virulence genes in pathogenic bacteria for use in a Helicobacter pylori vaccine

Anadis is paying US$100,000 up front, and will equally split any revenues with Microscience (10/10**)

Modex Therapeutics Ltd. (Switzerland; SWX:MDXN)

Eukarion Inc.*

Exclusive license agreement for worldwide rights to a small molecule for the prevention and treatment of radiation-induced skin damage

Modex will develop the compound into a topical protective treatment for radiation patients; Modex plans to begin a Phase I trial next year (10/5)

Morphochem AG (Germany)*

Automated Cell Inc.*

Agreement to identify, optimize and produce small-molecule drug candidates through a joint- development program

Candidates will be produced through a combination of Automated Cell's Protein Function Discovery Platform and Morphochem's chemical genomics program; companies have begun work in oncology and will share ownership of any candidates (10/16)

MorphoSys AG (Germany; Neuer Markt:MOR)

Oridis Biomed Forschungs-und Entwick-lungs GmbH (Austria)*

Agreement to provide MorphoSys with access to one of the world's largest tissue banks

MorphoSys will apply its HuCal technology to make antibodies to candidate targets, which Oridis Biomed will use to perform high-throughput protein expression analysis; Oridis will receive a license to the HuCal technology and will have access to certain antibodies from MorphoSys (9/17)

NeoGenesis Drug Discovery Inc.*

Tularik Inc. (TLRK)

Agreement in which Tularik will provide disease targets to Neo-Genesis, which will screen for small-molecule drug candidates of those targets

Tularik is providing research funding; Neo-Genesis may receive milestones and royalty payments on products developed by Tularik (9/26)

NetGenics Inc.*

Paradigm Genetics Inc. (PDGM)

Agreement for a multiseat DiscoveryCenter license

Paradigm is one of the first customers of the NetGenics integration software (10/1)

Neurochem Inc. (Canada; TSE:NRM)

Select Therapeutics Inc. (AMEX:XZL)

Collaboration aimed at the discovery of a vaccine intended to prevent the development and progression of Alzheimer's disease

Neurochem will provide Alzheimer's disease antigens from its proprietary library; Select will use its Verovax technology to target antigens isolated by Neurochem directly to dendritic cells (10/4)

November AG (Germany; Neuer Markt:NBX)

MediRox AB (Sweden)*

Agreement granting exclusive rights to MediRox for further development and marketing of novi quick

November will receive a percentage of any sales (10/17**)

Ocean Pharmaceuticals Inc.*

Diabact AB (Sweden)*

Licensing agreement for U.S. rights to a new sublingual/bioadhesive technology

Financial terms were not disclosed (9/10)

Omnimmune Corp.*

CytoGenix Inc. (OTC BB: CYGX)

Research agreement in which Omnimmune will use its antibodies to carry CytoGenix's DNA strands to treat cancer

Each company will be responsible financially for part of the research (8/28)

Orchid BioSciences Inc. (ORCH)

Ellipsis Biotherapeutics Corp. (Canada)*

SNP and pharmacogenomics collaboration

Orchid will work with Ellipsis to conduct high-throughput SNP genotyping and to construct high-density chromosome maps using samples provided by Ellipsis; the focus initially will be on inflammatory bowel disease; Orchid has rights for diagnostic applications (10/10)

Oxagen Ltd. (UK)*

Cerylid Biosciences Ltd. (Australia)*

Collaboration to investigate the genetics of endometriosis

The study will include more than 1,300 families in which at least two sisters are affected with endometriosis, together with their relatives (8/28)

Oxagen Ltd. (UK)*

Isis Innovation (technology transfer arm of Oxford University)*

Agreement for exclusive rights to a series of patents

The patents cover gene polymorphisms with potential association to Oxagen's work in complex inflammatory and autoimmune disease areas; Isis received an up-front payment and may receive further payments and royalties (10/16)

Pharmacopeia Inc. (PCOP)

Ester Neurosciences Ltd.*

Research and development agreement that will focus on neurological diseases involving the neuropathological upregulation of Ester's proprietary target, a variant of acetyl-cholinesterase

Pharmacopeia will receive research funding and may receive additional payments for identifying active compounds, as well as for achieving other milestones; it also will receive royalties (10/23)

Physiome Sciences Inc.*

3rd Millennium Inc.*

Licensing agreement for the PathwayPrism biological modeling technology to use in conjunction with data integration technology

It will allow 3rd Millennium and its academic collaborators to visualize and simulate pathways and associated networks related to Huntington's disease (8/28)

Plexus Vaccine Inc.*

Molsoft LLC*

Licensing agreement to discover and commercialize new interventional strategies for global infectious diseases, for drug-resistant microbes and for chronic diseases associated with cryptic pathogens

Using Molsoft's software, Plexus is developing Virtual Epitope databases of molecular targets for in silico design of structural mimics that can be readily synthesized, tested and formulated as vaccines (9/11)

Proteome Systems Inc. (Australia)*

Protagen AG (Germany)*

Collaboration involving the exchange of analysis of post-translational modifications of proteins

Proteome Systems gains access to Protagen's methodology and technology for the analysis of protein phosphorylation; Protagen will have access to Proteome System's methodology and technology for the analysis of protein glycosylation (9/21)

Qiagen NV (the Netherlands; QGENF)

Kreatech biotechnology BV (the Netherlands)*

Agreement granting Qiagen an exclusive license to Kreatech's Universal Linkage System labeling technologies and products

The products will be used in combination with Qiagen's resonance light scattering products licensed from Genicon Biosciences; Qiagen also acquired nonexclusive rights to develop and sell ULS products for labeling and detecting nucleic acids as well as proteins in microarray applications (10/17**)

Rigel Pharmaceuticals Inc. (RIGL)

Evotec OAI AG (Germany; Neuer Markt: ligases EVT)

Medicinal chemistry agreement for the optimization of small molecules focused on inhibitors of ubiquitin

Rigel will provide funding for Evotec for services, and Evotec may receive milestone payments (10/2)

SangStat Inc. (SANG)

Endocyte Inc.*

Agreement that grants Endocyte a nonexclusive, worldwide license to commercialize vitamin-based treatments using SangStat's complexine technology

Endocyte has the right to sublicense the technology; financial terms include license fees and royalties on sales (10/2)

Seattle Genetics Inc. (SGEN)

Proacta Therapeutics (New Zealand)*

Agreement to license certain cell-killing drugs

Seattle Genetics intends to evaluate the synthetic drugs as product candidates; it will have exclusive development, manufacturing and worldwide commercialiation rights to any products using the drugs (10/22)

Sequitur Inc.*

Discovery Genomics Inc.*

Agreement focused on screening antisense compounds to elucidate gene function in zebra fish

Sequitur will retain rights to discoveries of gene function in the areas of bone, hematopoiesis and obesity; Discovery Genomics will retain rights relating to the balance of vertebrate disease studies in the zebra fish model (9/26)

Sicor Inc. (SCRI)

Biomedical Frontiers Inc.*

Licensing agreement for a novel iron chelator drug candidate for potential use in treating iron overload in patients with transfusion-dependent sickle cell anemia and thalassemia

Terms of the agreement were not disclosed (9/26)

Structural Bioinformatics Inc.*

ChemNavigator Inc.*

Agreement to combine SBI's technologies in 3-dimensional computational proteomics with ChemNavigator's technologies in chemistry

The companies will share any generated revenues (9/5)

Structural GenomiX Inc.*

Compaq Computer Corp. (NYSE:CPQ)

Multimillion-dollar agreement to develop SGX's structural informatics systems

SGX will purchase a complete Compaq technology solution, which will assist the company and its partners in target identification and validation, lead selection and screening, and optimization of compounds for binding and selectivity (9/20)

Symyx Technologies Inc. (SMMX)

Prolinx Inc.*

Nonexclusive license agreement under which Prolinx intends to commercialize products incorporating a polymer developed by Symyx

Prolinx intends to launch substrates and protein arrays using the Symyx material before the end of the year, and to start receiving royalties from the sale of these products in early 2002 (10/1)

Synt:em (France)*

Boston Life Sciences Inc. (BLSI)

Research collaboration that will use Synt:em's peptide vector technology, Pep:trans, to improve delivery of a novel central nervous system diagnostic into the brain

The companies will fund certain percentages of costs, and will derive a defined split of potential revenue and royalties from marketed products; Synt:em will be paid for access to Pep:trans (10/10)

Tangerine Technologies Inc.*

ImClone Systems Inc. (IMCL)

Agreement to license Tangerine's OligoBuyer

ImClone will use OligoBuyer to specify, order and track its purchases of custom-configured strands of DNA and RNA (9/19)

Thales Industrial Services (France)*

Proteus International (France)*

Collaboration to develop a novel system using genetic technologies to detect and monitor biological terrorism

The collaboration has been entered into with-in the framework of a public tender from the French Direction General des Armees of the Department of Defense of the French Republic (9/17)

The PSMA Development LLC (joint venture between Progenics Pharmaceuticals Inc., PGNX; and Cytogen Corp., CYTO)

AlphaVax Human Vaccines Inc.*

Exclusive worldwide licensing agreement for the AlphaVax Replicon Vector system

The system will be used to create a therapeutic prostate cancer vaccine using PSMA's prostate-specific cancer antigen (9/6)

TranXenoGen Inc.*

Amgen Inc. (AMGN)

Collaboration to produce a proprietary monoclonal antibody

This is the fourth such deal for TranXeno-Gen, which specializes in the production of pharmaceutical proteins in hen eggs (9/12**)

Tranzyme Inc.*

Active Pass Pharmaceuticals Inc. (Canada)*

Collaboration in the areas of gene expression and drug discovery

The alliance will use Tranzyme's TexT in support of the ABC transporter chemogenomic program at Active Pass, which will provide multiple sets of ABC transporter gene sequences; Tranzyme will deliver these genes into mammalian cells and express and purify the proteins using its gene expression technology (9/20)

Tranzyme Inc.*

NeoGenesis Drug Discovery Inc.*

Collaboration combining Tranzyme's expertise in protein expression with NeoGenesis' chemical genomics

TExT will be used to bolster NeoGenesis' chemistry-based genomics program; Neo-Genesis will supply Tranzyme with multiple sets of therapeutic, disease-associated gene sequences, which Tranzyme will test on different mammalian cells (8/28)

Vical Inc. (VICL)

Ichor Medical Systems Inc.*

Agreement to develop products based on its naked DNA technology

Ichor will deliver the products using its electroporation systems (10/11)

ViroLogic Inc. (VLGC)

Triangle Pharmaceuticals Inc. (VIRS)

Agreement to assist in clinical evaluation of new anti-HIV agents being developed by Triangle

Triangle will use ViroLogic's PhenoSense HIV phenotypic drug resistance assay to evaluate the effectiveness of its investigational nucleoside reverse transcriptase inhibitors (9/20)

Vitrolife AB (Sweden; SSE:VITR)

Millenium Biologix Inc. (Canada)*

Agreement for the development and testing of Vitrolife's culture media for use in human tissue engineering, particularly cartilage and bone

The agreement will cover a period of comprehensive testing and evaluation of candidate media produced by Vitrolife, based on models established by Millenium (8/28)

Xenon Genetics Inc. (Canada)*

Discovery Partners International Inc. (DPII)

Drug discovery agreement to provide high-throughput screening, chemistry and informatics services to Xenon's drug discovery program

Financial details were not disclosed (9/27)

Xenon Genetics Inc. (Canada)*

QuantaNova Canada Ltd. (Canada)*

Agreement in which Xenon acquired QuantaNova's lipid metabolism drug discovery program

Xenon paid cash for the program (10/24)


Dompe SpA (Italy)*

Nonexclusive licensing agreement for the use of XOMA's patented technology for biopharmaceutical production

Dompe is using the technology in developing a fully human Fab for radioimmuno therapy of ovarian carcinoma (9/18)


# This chart does not include agreements that involve agricultural product development.

* Private companies are indicated with an asterisk.

** Denotes the date the item ran in BioWorld International.

Unless otherwise noted, the trading symbols listed for public biotechnology companies are on the Nasdaq market.

AMEX = American Stock Exchange; CSE = Copenhagen Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over the Counter Bulletin Board; SSE = Swedish Stock Exchange; SWX = Swiss Stock Exchange; TSE = Toronto Stock Exchange